Cholangiocarcinoma with an FGFR2 phenotype: outcomes in patients following surgical resection

Presenter: Rory Smoot MD | Mayo Clinic, Rochester Background: Cholangiocarcinoma (CCA) is an aggressive biliary cancer that has a dismal prognosis. Definitive treatment continues to rely on surgical resection as intent cure. Despite these efforts, CCA be deadly disease with 5 year survival nearing 10%. traditionally defined according anatomic location; intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Multiple studies have shown varying mutational profiles among CCAs. Specifically, FGFR2 fusion events appear more frequently observed in iCCA. Our aim was assess the outcomes surgically resected patients definable status. Methods: Surgically from single institution were retrospectively reviewed between 2008 and 2014. FGFR rearrangements detected using fluorescence situ hybridization (FISH) break-apart assay. Data included patient demographics, tumor pathology, treatment, disease-free (DFS) overall (OS), Descriptive analysis performed Fisher’s exact test, chi square t-Student, while OS DFS calculated by Kaplan-Meier method differences evaluated Log- Rank test. Cox proportional hazard model used identify prognostics factors. Results: One hundred fifty underwent for of these, 95 had Twelve (13%) iCCA found fusion, none which treated targeted therapy. A not identified any pCCA dCCA cases. rearrangement likely present younger (53.08 vs. 62.34 years, p = 0.012) females (83.3 49.4%, 0.033) patients. When compared negative fusions, fusions longer (83 32%, 0.009) 10 (46 22%, 0.04) OS, respectively. Similarly, also increased (68 33% 25 %, 0.02,), Multivariate Regression status strongest independent factor associated improved (HR 0.23, 0.09-0.62, 0.003) 0.18, 0.05-0.67, 0.01). Conclusion: prognostic well free